540 related articles for article (PubMed ID: 30895619)
21. RNF144A suppresses ovarian cancer stem cell properties and tumor progression through regulation of LIN28B degradation via the ubiquitin-proteasome pathway.
Li Y; Wang J; Wang F; Chen W; Gao C; Wang J
Cell Biol Toxicol; 2022 Oct; 38(5):809-824. PubMed ID: 33978933
[TBL] [Abstract][Full Text] [Related]
22. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
23. Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling.
Wu G; Cao L; Zhu J; Tan Z; Tang M; Li Z; Hu Y; Yu R; Zhang S; Song L; Li J
Clin Cancer Res; 2019 Feb; 25(3):1022-1035. PubMed ID: 30279231
[TBL] [Abstract][Full Text] [Related]
24. MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition.
Cao L; Wan Q; Li F; Tang CE
BMB Rep; 2018 Sep; 51(9):456-461. PubMed ID: 30037365
[TBL] [Abstract][Full Text] [Related]
25. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype.
Zhu X; Shen H; Yin X; Yang M; Wei H; Chen Q; Feng F; Liu Y; Xu W; Li Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):81. PubMed ID: 30770776
[TBL] [Abstract][Full Text] [Related]
26. The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-κB signaling pathway.
He S; Niu G; Shang J; Deng Y; Wan Z; Zhang C; You Z; Shen H
J Exp Clin Cancer Res; 2017 Oct; 36(1):137. PubMed ID: 28978336
[TBL] [Abstract][Full Text] [Related]
27. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
Lin M; Xia B; Qin L; Chen H; Lou G
DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
Zhao J; Liu HR
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
[TBL] [Abstract][Full Text] [Related]
30. USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway.
Pei L; Zhao F; Zhang Y
Apoptosis; 2024 Feb; 29(1-2):210-228. PubMed ID: 38087046
[TBL] [Abstract][Full Text] [Related]
31. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
32. LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model.
Mehdi S; Macdonald E; Galpin K; Landry DA; Rodriguez G; Vanderhyden B; Bachvarov D
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679765
[TBL] [Abstract][Full Text] [Related]
33. SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma.
Zhang PF; Wu J; Luo JH; Li KS; Wang F; Huang W; Wu Y; Gao SP; Zhang XM; Zhang PN
Aging (Albany NY); 2019 Oct; 11(19):8204-8216. PubMed ID: 31581131
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
35. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
36. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
37. BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.
Han W; Zhang Y; Niu C; Guo J; Li J; Wei X; Jia M; Zhi X; Yao L; Meng D
Cancer Lett; 2019 Mar; 445():45-56. PubMed ID: 30654010
[TBL] [Abstract][Full Text] [Related]
38. Chromatin target of protein arginine methyltransferase regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer.
Feng X; Li L; Wang L; Luo S; Bai X
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910850
[TBL] [Abstract][Full Text] [Related]
39. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
40. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]